GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation - Q4 FY 22-23 & FY 22-23. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release on the Audited Financial Results of the Company for the quarter and year ended March 31, 2023. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Outcome for Outcome Of The Board Meeting - May 19, 2023
The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 19, 2023, which commenced at 02.00 p.m. and concluded at 06.40 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2023. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com 2. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting. GLENMARK PHARMACEUTICALS LTD. - 532296 - Audited Financial Results For The Quarter And Year Ended March 31, 2023
The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 19, 2023, which commenced at 02.00 p.m. and concluded at 06.40 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2023. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com 2. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
Glenmark Pharma share price hits 52-week high; time to buy the stock?
Glenmark Pharmaceuticals is expected to release its March quarter numbers on May 19. The quarterly performance and management commentary will be the key trigger for the stock. GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 By Glenmark Pharmaceuticals Limited (GPL) In Respect Of Incorporation Of A Wholly Owned Subsidiary Company
Pursuant to the provisions of Regulation 30 of SEBI Listing Regulations, we wish to inform you that a wholly-owned subsidiary company of GPL in the name of 'Glenmark Healthcare Limited' has been incorporated on May 12, 2023 under corporate identity number U21001MH2023PLC402796 ('WOS'). The details/disclosures in respect of the said WOS, as required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided in the enclosed Annexure.
Glenmark Pharmaceuticals shares hit 52-week high as street expects good Q4 numbers; check details
Glenmark Pharma Share Price: The stock closed at 615.80 apiece, up 35.75 or 6.16% on BSE on Friday. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, May 22, 2023 at 9:30 a.m. - 10:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
As per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2023 to May 21, 2023 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31, 2023.